Jump to content

Aspirin

From Wikipedia, the free encyclopedia

This is an old revision of this page, as edited by 91.106.223.11 (talk) at 12:11, 5 November 2009 (→Other effects). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

"Asprin" redirects here. For the author, see Robert Asprin.
Aspirin
Clinical data
Other names2-acetyloxybenzoic acid
acetylsalicylate
acetylsalicylic acid
O-acetylsalicylic acid
Pregnancy
category
  • AU: C
Routes of
administration		Most commonly oral, also rectal. Lysine acetylsalicylate may be given IV or IM
ATC code
Legal status
Legal status
Pharmacokinetic data
BioavailabilityRapidly and completely absorbed
Protein binding99.6%
MetabolismHepatic
Elimination half-life300–650 mg dose: 3.1–3.2 h
1 g dose: 5 h
2 g dose: 9 h
ExcretionRenal
Identifiers
  • 2-acetoxybenzoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
CompTox Dashboard (EPA)
ECHA InfoCard100.000.059 Edit this at Wikidata
Chemical and physical data
FormulaC9H8O4
Molar mass180.157 g/mol g·mol−1
3D model (JSmol)
Density1.40 g/cm3
Melting point135 °C (275 °F)
Boiling point140 °C (284 °F) (decomposes)
Solubility in water3 mg/mL (20 °C)
  • O=C(Oc1ccccc1C(=O)O)C
  (verify)

Aspirin (USAN), also known as acetylsalicylic acid (Template:Pron-en, abbreviated ASA), is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication.

Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damage of the walls within blood vessels. Because the platelet patch can become too large and also block blood flow, locally and downstream, aspirin is also used long-term, at low doses, to help prevent heart attacks, strokes, and blood clot formation in people at high risk for developing blood clots.[1] It has also been established that low doses of aspirin may be given immediately after a heart attack to reduce the risk of another heart attack or of the death of cardiac tissue.[2][3]

The main undesirable side effects of aspirin are gastrointestinal ulcers, stomach bleeding, and tinnitus, especially in higher doses. In children and adolescents, aspirin is no longer used to control flu-like symptoms or the symptoms of chickenpox or other viral illnesses, because of the risk of Reye's syndrome.[4]

Aspirin was the first discovered member of the class of drugs known as non-steroidal anti-inflammatory drugs (NSAIDs), not all of which are salicylates, although they all have similar effects and most have inhibition of the enzyme cyclooxygenase as their mechanism of action. Today, aspirin is one of the most widely used medications in the world, with an estimated 40,000 tonnes of it being consumed each year.[5] In countries where Aspirin is a registered trademark owned by Bayer, the generic term is acetylsalicylic acid (ASA).[6][7]

History

Main article: History of aspirin

A French chemist, Charles Frederic Gerhardt, was the first to prepare acetylsalicylic acid in 1853. In the course of his work on the synthesis and properties of various acid anhydrides, he mixed acetyl chloride with a sodium salt of salicylic acid (sodium salicylate). A vigorous reaction ensued, and the resulting melt soon solidified.[8] Since no structural theory existed at that time, Gerhardt called the compound he obtained "salicylic-acetic anhydride" (wasserfreie Salicylsäure-Essigsäure). This preparation of aspirin ("salicylic-acetic anhydride") was one of the many reactions Gerhardt conducted for his paper on anhydrides and he did not pursue it further.

Advertisement for Aspirin, Heroin, Lycetol, Salophen

Six years later, in 1859, von Gilm obtained analytically pure acetylsalicylic acid (which he called "acetylierte Salicylsäure", acetylated salicylic acid) by a reaction of salicylic acid and acetyl chloride.[9] In 1869 Schröder, Prinzhorn and Kraut repeated both Gerhardt's (from sodium salicylate) and von Gilm's (from salicylic acid) syntheses and concluded that both reactions gave the same compound—acetylsalicylic acid. They were first to assign to it the correct structure with the acetyl group connected to the phenolic oxygen.[10]

In 1897, scientists at the drug and dye firm Bayer began investigating acetylsalicylic acid as a less-irritating replacement for standard common salicylate medicines. By 1899, Bayer had dubbed this drug Aspirin and was selling it around the world.[11] The name Aspirin is derived from A = Acetyl and "Spirsäure" = an old (German) name for salicylic acid.[12] Aspirin's popularity grew over the first half of the twentieth century, spurred by its effectiveness in the wake of the Spanish flu pandemic of 1918, and aspirin's profitability led to fierce competition and the proliferation of aspirin brands and products, especially after the American patent held by Bayer expired in 1917.[13][14]

Aspirin's popularity declined after the market releases of paracetamol (acetaminophen) in 1956 and ibuprofen in 1969.[15] In the 1960s and 1970s, John Vane and others discovered the basic mechanism of aspirin's effects, while clinical trials and other studies from the 1960s to the 1980s established aspirin's efficacy as an anti-clotting agent that reduces the risk of clotting diseases.[16] Aspirin sales revived considerably in the last decades of the twentieth century, and remain strong in the twenty-first, thanks to widespread use as a preventive treatment for heart attacks and strokes.[17]

Trademark in most countries

As part of war reparations specified in the 1919 Treaty of Versailles following Germany's surrender after World War I, Aspirin (along with Heroin) lost its status as a registered trademark in France, Russia, the United Kingdom, and the United States, where it became a generic name and can be spelled in lower case.[18][19][20] Today, "aspirin" is a generic word in Australia, Argentina, France, India, Ireland, New Zealand, Pakistan, the Philippines, South Africa, United Kingdom and the United States.[21] Aspirin, with a capital "A", remains a registered trademark of Bayer in Germany, Canada, Mexico, and in over 80 other countries, where the trademark is owned by Bayer.[22][23][24] Since the word "aspirin" has become generic in many countries, Bayer has embarked on an aggressive trademark protection campaign in the United States and owns more than 1,000 U.S. trademarks on various pharmaceutical drugs.[25]

Therapeutic uses

Headache

Aspirin is one of the first-line drugs used in the treatment of migraine, bringing relief in 50–60% of the cases.[26] It is as effective as a newer triptan medication sumatriptan (Imitrex)[27] and other painkillers such as paracetamol[28] or ibuprofen.[29] The combination of aspirin, paracetamol and caffeine (Excedrin) is even more potent. For the treatment of migraine headache, this formulation works better than any of its three components taken separately,[28] better than ibuprofen[30] and better than sumatriptan. Similarly to all other medications for migraine, it is recommended to take aspirin at the first signs of the headache, and it is the way these medications were used in the comparative clinical trials. [31]

Aspirin alleviates pain in 60-75% patients with episodic tension headache.[32][33] It is equivalent to paracetamol in that respect, except for the higher frequency of gastrointestinal side effects.[33] Comparative clinical trials indicated that metamizole and ibuprofen may relieve pain faster than aspirin, although the difference becomes insignificant after about 2 hours.[32][34] The combination of aspirin, paracetamol and caffeine (Excedrin) is still more effective, but at the cost of more stomach discomfort, nervousness and dizziness.[35]

Pain

In general, aspirin works well for dull, throbbing pain; it is ineffective for pain caused by most muscle cramps, bloating, gastric distension and acute skin irritation.[36] The most studied example is pain after surgery such as tooth extraction, for which the highest allowed dose of aspirin (1 g) is equivalent to 1 g of paracetamol, 60 mg of codeine and 5 mg of oxycodone. Combination of aspirin and caffeine, generally, affords greater pain relief than aspirin alone. Effervescent aspirin alleviates pain much faster than aspirin in tablets (15-30 min vs. 45-60 min).[37]

Nevertheless, as a post-surgery painkiller, aspirin is inferior to ibuprofen. Aspirin has higher gastrointestinal toxicity than ibuprofen. The maximum dose of aspirin (1 g) provides weaker pain relief than an intermediate dose of ibuprofen (400 mg), and this relief does not last as long.[37] A combination of aspirin and codeine may have a slightly higher analgesic effect than aspirin alone; however, this difference is not clinically meaningful.[38] It appears that ibuprofen is at least equally, and possibly more, effective than this combination.[39]

According to a meta-analysis of clinical trials for menstrual pain, aspirin demonstrated higher efficacy than placebo but lower one than ibuprofen or naproxen, although maximum doses of aspirin were never used in these trials. The authors concluded that ibuprofen has the best risk-benefit ratio.[40]

Aspirin did not ease pain during cycling exercise,[41] while caffeine, surprisingly, was very effective.[42][43] Similarly, aspirin, codeine or paracetamol were not better than placebo for muscle soreness after exercise.[44]

Other uses

Although aspirin has been used to combat fever and pains associated with common cold for more than 100 years, only recently its efficacy was confirmed in controlled clinical trials on adults. 1 g of aspirin, on average, reduced the oral body temperature from 39.0°C to 37.6°C after 3 hours. The relief began after 30 minutes, and after 6 hours the temperature still remained below 37.8°C. Aspirin also helped with "achiness", discomfort and headache,[45] and with sore throat pain, for those who had it.[46] Aspirin was indistinguishable from paracetamol in any respect, except for, possibly, slightly higher rate of sweating and gastrointestinal side effects.[45]

Fever and joint pain of acute rheumatic fever respond extremely well, often within three days, to high doses of aspirin. The therapy usually lasts for 1-2 weeks; and only in about 5% of the cases it has to continue for longer that six months. After the fever and pain has subsided, the aspirin treatment is unnecessary as it does not decrease the incidence of heart complications and residual rheumatic heart disease.[47] In addition, the high doses of aspirin used cause liver toxicity in about 20% of the treated children,[48][49] who are the majority of rheumatic fever patients, and increase the risk of them developing Reye's syndrome.[47] Naproxen was shown to be as effective as aspirin and less toxic; however, due to the limited clinical experience, naproxen is recommended only as a second-line treatment.[47][50]

Along with rheumatic fever, Kawasaki disease remains one of the few indications for aspirin use in children, although even this use has been questioned by some authors.[51] In the United Kingdom, the only indications for aspirin use in children and adolescents under 16 are Kawasaki disease and prevention of blood clot formation.

In lower doses, aspirin (or its equivalents, e.g., carbasalate calcium) also inhibits platelet aggregation, and has been shown to reduce the incidence of transient ischemic attacks and unstable angina in men, and can be used prophylactically. It is also used in the treatment of pericarditis, coronary artery disease, and acute myocardial infarction.[52][53] Low doses of aspirin are also recommended for the prevention of stroke, primary prevention of cardiovascular disease,[54] as well as myocardial infarction in patients with diagnosed cardiovascular disease.


Experimental

Aspirin has been theorized to reduce cataract formation in diabetic patients, but one study showed it was ineffective for this purpose.[55] The role of aspirin in reducing the incidence of many forms of cancer has also been widely studied. In several studies, aspirin use did not reduce the incidence of prostate cancer.[56][57] Its effects on the incidence of pancreatic cancer are mixed; one study published in 2004 found a statistically significant increase in the risk of pancreatic cancer among women,[58] while a meta-analysis of several studies, published in 2006, found no evidence that aspirin or other NSAIDs are associated with an increased risk for the disease.[59] The drug may be effective in reduction of risk of various cancers, including those of the colon,[60][61][62][63] lung,[64][65] and possibly the upper GI tract, though some evidence of its effectiveness in preventing cancer of the upper GI tract has been inconclusive.[66][66][67] Its preventative effect against adenocarcinomas may be explained by its inhibition of COX-2 enzymes expressed in them.[68]

In a 2009 article published by the Journal of Clinical Investigation, it was found that aspirin might prevent liver damage. In their experiment, scientists from Yale University and The University of Iowa induced damage in certain liver cells called hepatocytes using excessive doses of acetaminophen. This caused hepatoxicity and hepatocyte death which triggered an increase in the production of TLR9. The expression of TLR9 caused an inflammatory cascade involving pro–IL-1β and pro-IL-18. Aspirin was found to have a protective effect on hepatocytes because it led to the "downregulation of proinflammatory cytokines"[69].

In another 2009 article published by the Journal of the American Medican Association, it was found that men and women who regularly took aspirin after colorectal cancer diagnosis had lower risk of overall and colorectal cancer death compared to patients not using aspirin.[70][71]

Veterinary uses

Aspirin has been used to treat pain and arthritis in veterinary medicine, primarily in dogs, although it is often not recommended for this purpose, as there are newer medications available with fewer side effects in these animals. Dogs, for example, are particularly susceptible to the gastrointestinal side effects associated with salicylates.[72] Horses have also been given aspirin for pain relief, although it is not commonly used owing to its relatively short-lived analgesic effects. Horses are also fairly sensitive to the gastrointestinal side effects. Nevertheless, it has shown promise in its use as an anticoagulant, mostly in cases of laminitis.[73] Aspirin should only be used in animals under the direct supervision of a veterinarian. Aspirin should never be given to cats because they lack the ability to form glucuronide conjugates, which makes it more likely that aspirin will be toxic. Toxicity may be reduced by administering dosages at longer intervals.[74]

Mechanism of action

Main article: Mechanism of action of aspirin
Structure of COX-2 inactivated by Aspirin. In the active site of each of the two monomers, Serine 530 has been acetylated. Also visible is the salicylic acid which has transferred the acyl group, and the heme cofactor.

Discovering the mechanism

In 1971, British pharmacologist John Robert Vane, then employed by the Royal College of Surgeons in London, showed that aspirin suppressed the production of prostaglandins and thromboxanes.[75][76] For this discovery, he was awarded both a Nobel Prize in Physiology or Medicine in 1982 and a knighthood.

Suppression of prostaglandins and thromboxanes

Aspirin's ability to suppress the production of prostaglandins and thromboxanes is due to its irreversible inactivation of the cyclooxygenase (COX) enzyme. Cyclooxygenase is required for prostaglandin and thromboxane synthesis. Aspirin acts as an acetylating agent where an acetyl group is covalently attached to a serine residue in the active site of the COX enzyme. This makes aspirin different from other NSAIDs (such as diclofenac and ibuprofen), which are reversible inhibitors.

Low-dose, long-term aspirin use irreversibly blocks the formation of thromboxane A2 in platelets, producing an inhibitory effect on platelet aggregation. This anticoagulant property makes aspirin useful for reducing the incidence of heart attacks.[77] 40 mg of aspirin a day is able to inhibit a large proportion of maximum thromboxane A2 release provoked acutely, with the prostaglandin I2 synthesis being little affected; however, higher doses of aspirin are required to attain further inhibition.[78]

Prostaglandins are local hormones produced in the body and have diverse effects in the body, including the transmission of pain information to the brain, modulation of the hypothalamic thermostat, and inflammation. Thromboxanes are responsible for the aggregation of platelets that form blood clots. Heart attacks are primarily caused by blood clots, and low doses of aspirin are seen as an effective medical intervention for acute myocardial infarction. The major side-effect of this is that because the ability of blood to clot is reduced, excessive bleeding may result from the use of aspirin.

COX-1 and COX-2 inhibition

There are at least two different types of cyclooxygenase: COX-1 and COX-2. Aspirin irreversibly inhibits COX-1 and modifies the enzymatic activity of COX-2. Normally COX-2 produces prostanoids, most of which are pro-inflammatory. Aspirin-modified COX-2 produces lipoxins, most of which are anti-inflammatory. Newer NSAID drugs called COX-2 selective inhibitors have been developed that inhibit only COX-2, with the intent to reduce the incidence of gastrointestinal side-effects.[5]

However, several of the new COX-2 selective inhibitors, such as Vioxx, have been withdrawn recently, after evidence emerged that COX-2 inhibitors increase the risk of heart attack. It is proposed that endothelial cells lining the microvasculature in the body express COX-2, and, by selectively inhibiting COX-2, prostaglandin production (specifically PGI2; prostacyclin) is downregulated with respect to thromboxane levels, as COX-1 in platelets is unaffected. Thus, the protective anti-coagulative effect of PGI2 is removed, increasing the risk of thrombus and associated heart attacks and other circulatory problems. Since platelets have no DNA, they are unable to synthesize new COX once aspirin has irreversibly inhibited the enzyme, an important difference with reversible inhibitors.

Additional mechanisms

Aspirin has been shown to have at least three additional modes of action. It uncouples oxidative phosphorylation in cartilaginous (and hepatic) mitochondria, by diffusing from the inner membrane space as a proton carrier back into the mitochondrial matrix, where it ionizes once again to release protons.[79] In short, aspirin buffers and transports the protons. When high doses of aspirin are given, aspirin may actually cause fever owing to the heat released from the electron transport chain, as opposed to the antipyretic action of aspirin seen with lower doses. Additionally, aspirin induces the formation of NO-radicals in the body, which have been shown in mice to have an independent mechanism of reducing inflammation. This reduced leukocyte adhesion, which is an important step in immune response to infection; however, there is currently insufficient evidence to show that aspirin helps to fight infection.[80] More recent data also suggests that salicylic acid and its derivatives modulate signaling through NF-κB.[81] NF-κB is a transcription factor complex that plays a central role in many biological processes, including inflammation.

Effects upon Hypothalamic-Pituitary-Adrenal Activity

Aspirin reduces the effects of vasopressin[82] and increases those of naloxone[83] upon the secretion of ACTH and cortisol by the hypothalamic-pituitary-adrenal axis. It has been suggested that this occurs through an interaction with endogenous prostaglandins and their role in regulating the HPA axis.[82]

Chemistry

Aspirin is an acetyl derivative of salicylic acid that is a white, crystalline, weakly acidic substance, with melting point 135°C. Acetylsalicylic acid decomposes rapidly in solutions of ammonium acetate or of the acetates, carbonates, citrates or hydroxides of the alkali metals. Acetylsalicylic acid is stable in dry air, but gradually hydrolyses in contact with moisture to acetic and salicylic acids. In solution with alkalis, the hydrolysis proceeds rapidly and the clear solutions formed may consist entirely of acetate and salicylate.[84]

Synthesis

The synthesis of aspirin is classified as an esterification reaction. Salicylic acid is treated with acetic anhydride, an acid derivative, causing a chemical reaction that turns salicylic acid's phenol group into an acetyl group, (R-OH → R-OCOCH3). This process yields aspirin and acetic acid, which is considered a byproduct of this reaction. Small amounts of sulfuric acid (and occasionally phosphoric acid) are almost always used as a catalyst. This method is commonly employed in undergraduate teaching labs.[85]

Formulations containing high concentrations of aspirin often smell like vinegar.[86] This is because aspirin can decompose through hydrolysis in moist conditions, yielding salicylic acid and acetic acid.[87]

The acid dissociation constant (pKa) for acetylsalicylic acid is 3.5 at 25 °C.[88]

Polymorphism

Polymorphism, or the ability of a substance to form more than one crystal structure, is important in the development of pharmaceutical ingredients. Many drugs are receiving regulatory approval for only a single crystal form or polymorph. For a long time, only one crystal structure for aspirin was known, although there had been indications that aspirin might have a second crystalline form since the 1960s. The elusive second polymorph was first discovered by Vishweshwar and coworkers in 2005,[89] and fine structural details were given by Bond et al.[90] A new crystal type was found after attempted co-crystallization of aspirin and levetiracetam from hot acetonitrile. The form II is only stable at 100 K and reverts back to form I at ambient temperature. In the (unambiguous) form I, two salicylic molecules form centrosymmetric dimers through the acetyl groups with the (acidic) methyl proton to carbonyl hydrogen bonds, and in the newly claimed form II, each salicylic molecule forms the same hydrogen bonds with two neighboring molecules instead of one. With respect to the hydrogen bonds formed by the carboxylic acid groups both polymorphs form identical dimer structures.

Pharmacokinetics

Salicylic acid is a weak acid, and very little of it is ionized in the stomach after oral administration. Acetylsalicylic acid is poorly soluble in the acidic conditions of the stomach, which can delay absorption of high doses for 8 to 24 hours. In addition to the increased pH of the small intestine, aspirin is rapidly absorbed there owing to the increased surface area, which in turn allows more of the salicylate to dissolve. Owing to the issue of solubility, however, aspirin is absorbed much more slowly during overdose, and plasma concentrations can continue to rise for up to 24 hours after ingestion.[91][92][93]

About 50–80% of salicylate in the blood is bound by protein while the rest remains in the active, ionized state; protein binding is concentration-dependent. Saturation of binding sites leads to more free salicylate and increased toxicity. The volume of distribution is 0.1–0.2 l/kg. Acidosis increases the volume of distribution because of enhancement of tissue penetration of salicylates.[93]

As much as 80% of therapeutic doses of salicylic acid is metabolized in the liver. Conjugation with glycine forms salicyluric acid and with glucuronic acid forms salicyl acyl and phenolic glucuronide. These metabolic pathways have only a limited capacity. Small amounts of salicylic acid are also hydroxylated to gentisic acid. With large salicylate doses, the kinetics switch from first order to zero order, as metabolic pathways become saturated and renal excretion becomes increasingly important.[93]

Salicylates are excreted mainly by the kidneys as salicyluric acid (75%), free salicylic acid (10%), salicylic phenol (10%) and acyl (5%) glucuronides, and gentisic acid (< 1%). When small doses (less than 250 mg in an adult) are ingested, all pathways proceed by first order kinetics, with an elimination half-life of about 2 to 4.5 hours.[94][95] When higher doses of salicylate are ingested (more than 4 g), the half-life becomes much longer (15–30 hours)[96] because the biotransformation pathways concerned with the formation of salicyluric acid and salicyl phenolic glucuronide become saturated.[97] Renal excretion of salicylic acid becomes increasingly important as the metabolic pathways become saturated, because it is extremely sensitive to changes in urinary pH. There is a 10 to 20 fold increase in renal clearance when urine pH is increased from 5 to 8. The use of urinary alkalinization exploits this particular aspect of salicylate elimination.[98]

Contraindications and resistance

Aspirin should not be taken by people who are allergic to ibuprofen or naproxen,[99][100] or who have salicylate intolerance[101][102] or a more generalized drug intolerance to NSAIDs, and caution should be exercised in those with asthma or NSAID-precipitated bronchospasm. Owing to its effect on the stomach lining, manufacturers recommend that people with peptic ulcers, mild diabetes, or gastritis seek medical advice before using aspirin.[99][103] Even if none of these conditions are present, there is still an increased risk of stomach bleeding when aspirin is taken with alcohol or warfarin.[99][100] Patients with hemophilia or other bleeding tendencies should not take aspirin or other salicylates.[99][103] Aspirin is known to cause hemolytic anemia in people who have the genetic disease glucose-6-phosphate dehydrogenase deficiency (G6PD), particularly in large doses and depending on the severity of the disease.[104][105] Use of aspirin during dengue fever is not recommended owing to increased bleeding tendency.[106] People with kidney disease, hyperuricemia, or gout should not take aspirin because aspirin inhibits the kidneys' ability to excrete uric acid and thus may exacerbate these conditions. Aspirin should not be given to children or adolescents to control cold or influenza symptoms as this has been linked with Reye's syndrome.[4]

For some people, aspirin does not have as strong an effect on platelets as for others, an effect known as aspirin resistance or insensitivity. One study has suggested that women are more likely to be resistant than men[107] and a different, aggregate study of 2,930 patients found 28% to be resistant.[108] A study in 100 Italian patients found that of the apparent 31% aspirin resistant subjects, only 5% were truly resistant, and the others were non-compliant.[109]

Adverse effects

Gastrointestinal

Aspirin use has been shown to increase the risk of gastrointestinal bleeding.[110] Although some enteric coated formulations of aspirin are advertised as being "gentle to the stomach", in one study enteric coating did not seem to reduce this risk.[110] Combining aspirin with other NSAIDs has also been shown to further increase this risk.[110] Using aspirin in combination with clopidogrel or warfarin also increases the risk of upper GI bleeding.[111]

Central effects

Large doses of salicylate, a metabolite of aspirin, have been proposed to cause tinnitus, based on the experiments in rats, via the action on arachidonic acid and NMDA receptors cascade.[112]

Reye's syndrome

Main article: Reye's syndrome

Reye's syndrome, a severe illness characterized by acute encephalopathy and fatty liver, can occur when children or adolescents are given aspirin for a fever or other illnesses or infections. From 1981 through 1997, 1207 cases of Reye's syndrome in under-18 patients were reported to the U.S. Centers for Disease Control and Prevention. Of these, 93% reported being ill in the three weeks preceding onset of Reye's syndrome, most commonly with a respiratory infection, chickenpox, or diarrhea. Salicylates were detectable in 81.9% of children for whom test results were reported.[113] After the association between Reye's syndrome and aspirin was reported and safety measures to prevent it (including a Surgeon General's warning and changes to the labeling of aspirin-containing drugs) were implemented, aspirin-taking by children declined considerably in the United States, as did the number of reported cases of Reye's syndrome; a similar decline was found in the United Kingdom after warnings against pediatric aspirin use were issued.[113] The United States Food and Drug Administration now recommends that aspirin (or aspirin-containing products) should not be given to anyone under the age of 12 who has a fever.[4]

Hives/swelling

For a small number of people, aspirin can result in symptoms that resemble an allergic reaction and include hives, swelling, and headache. The reaction is caused by salicylate intolerance and is not a true allergy but rather an inability to metabolize even small amounts of aspirin, resulting in an overdose.

Other effects

Aspirin can cause prolonged bleeding after operations for up to 10 days. In one study, thirty patients were observed after their various surgeries. Twenty of the thirty patients had to have an additional unplanned operation because of postoperative bleeding.[114] This diffuse bleeding was associated with aspirin alone or in combination with another NSAID in 19 out of the 20 who had to have another operation owing to bleeding after their operation. The average recovery time for the second operation was 11 days.

Aspirin can induce angioedema in some people. In one study, angioedema appeared 1–6 hours after ingesting aspirin in some of the patients participating in the study. However, when the aspirin was taken alone it did not cause angioedema in these patients; the aspirin had been taken in combination with another NSAID-induced drug when angioedema appeared.[115]

Aspirin causes an increased risk of cerebral microbleeds that is the appearance on MRI scans of 5-10 mm or smaller hypointense (dark holes) patches.[116][117] Such cerebral microbleeds are important since they often occur prior to ischemic stroke or intracerebral hemorrhage, Binswanger disease and Alzheimers Disease.

It is commonly held that the blood-thinning effects of aspirin mean an increased potential for vocal fold haemorrhaging. High load voice users (professional singers, actors etc) are thus often advised to avoid aspirin unless prescribed to thin the blood. [118]http://linkinghub.elsevier.com/retrieve/pii/S0892199700800351

Interactions

Aspirin is known to interact with other drugs. For example, acetazolamide and ammonium chloride have been known to enhance the intoxicating effect of salicyclates, and alcohol also increases the gastrointestinal bleeding associated with these types of drugs.[99][100] Aspirin is known to displace a number of drugs from protein binding sites in the blood, including the anti-diabetic drugs tolbutamide and chlorpropamide, the immunosuppressant methotrexate, phenytoin, probenecid, valproic acid (as well as interfering with beta oxidation, an important part of valproate metabolism) and any nonsteroidal anti-inflammatory drug. Corticosteroids may also reduce the concentration of aspirin. The pharmacological activity of spironolactone may be reduced by taking aspirin, and aspirin is known to compete with Penicillin G for renal tubular secretion.[119] Aspirin may also inhibit the absorption of vitamin C.[120][121][122]

Dosage

Coated 325 mg aspirin tablets

For adults doses are generally taken four times a day for fever or arthritis,[123] with doses near the maximal daily dose used historically for the treatment of rheumatic fever.[124] For the prevention of myocardial infarction in someone with documented or suspected coronary artery disease, much lower doses are taken once daily.[123]

New recommendations from the US Preventive Services Task Force (USPSTF, March, 2009) on the use of aspirin for the primary prevention of coronary heart disease encourage men aged 45–79 and women aged 55–79 to use aspirin when the potential benefit of a reduction in myocardial infarction (MI) for men or stroke for women outweighs the potential harm of an increase in gastrointestinal hemorrhage. Regular low dose (75 mg) aspirin users had a 25% lower risk of death from cardiovascular disease and a 14% lower risk of death from any cause. Low dose aspirin use was also associated with a trend toward lower risk of cardiovascular events, and lower aspirin doses (75 to 81 mg/day) may optimize efficacy and safety for patients requiring aspirin for long-term prevention[125].

In children with Kawasaki disease, aspirin is taken at dosages based on body weight, initially four times a day for up to two weeks and then at a lower dose once daily for a further six to eight weeks.[126]

Overdose

Main article: Aspirin poisoning

Aspirin overdose can be acute or chronic. In acute poisoning, a single large dose is taken; in chronic poisoning, higher than normal doses are taken over a period of time. Acute overdose has a mortality rate of 2%. Chronic overdose is more commonly lethal with a mortality rate of 25%; chronic overdose may be especially severe in children.[127] Toxicity is managed with a number of potential treatments including: activated charcoal, intravenous dexterous and normal saline, sodium bicarb, and dialysis.[128]

Compendial status

See also

Notes & References

  1. ^ Lewis, H D (1983-08-18). "Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study". The New England journal of medicine. 309 (7): 396–403. ISSN 0028-4793. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  2. ^ Julian, D G (1996-09-24). "A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): a multicentre unblinded randomised clinical trial". BMJ. 313 (7070). British Medical Journal: 1429–1431. PMID 8973228. Retrieved 2007-10-04. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  3. ^ Krumholz, Harlan M. (1995-11-15). "Aspirin in the Treatment of Acute Myocardial Infarction in Elderly Medicare Beneficiaries : Patterns of Use and Outcomes". Circulation. 92 (10): 2841–2847. PMID 7586250. Retrieved 2008-05-15. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  4. ^ a b c Macdonald S (2002). "Aspirin use to be banned in under 16 year olds". BMJ. 325 (7371): 988. doi:10.1136/bmj.325.7371.988/c. PMC 1169585. PMID 12411346.
  5. ^ a b Warner, T. D. (2002-10-15). "Cyclooxygenase-3 (COX-3): filling in the gaps toward a COX continuum?". Proc Natl Acad Sci U S A. 99 (21): 13371–3. doi:10.1073/pnas.222543099. PMID 12374850. Retrieved 2008-05-08. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  6. ^ http://www.wordconstructions.com/articles/health/aspirin.html
  7. ^ http://www.inta.org/index.php?option=com_content&task=view&id=202&Itemid=126&getcontent=5
  8. ^ Template:De icon Gerhardt C (1853). "Untersuchungen über die wasserfreien organischen Säuren". Annalen der Chemie und Pharmacie. 87: 149–179. doi:10.1002/jlac.18530870107.
  9. ^ Template:De icon von Gilm H (1859). "Acetylderivate der Phloretin- und Salicylsäure". Annalen der Chemie und Pharmacie. 112 (2): 180–185. doi:10.1002/jlac.18591120207.
  10. ^ Template:De icon Schröder, Prinzhorn, Kraut K (1869). "Uber Salicylverbindungen". Annalen der Chemie und Pharmacie. 150 (1): 1–20. doi:10.1002/jlac.18691500102.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  11. ^ Jeffreys, Diarmuid (August 11, 2005). Aspirin: The Remarkable Story of a Wonder Drug. Bloomsbury USA. p. 73. ISBN 1582346003.
  12. ^ Ueber Aspirin. Pflügers Archiv : European journal of physiology, Volume: 84, Issue: 11-12 (March 1, 1901), pp: 527-546.
  13. ^ Jeffreys, Aspirin, pp. 136–142 and 151-152
  14. ^ http://www.history.com/this-day-in-history.do?action=VideoArticle&id=52415
  15. ^ Jeffreys, Aspirin, pp. 212–217
  16. ^ Jeffreys, Aspirin, pp. 226–231
  17. ^ Jeffreys, Aspirin, pp. 267–269
  18. ^ "Treaty of Versailles, Part X, Section IV, Article 298". 1919-06-28. pp. Annex, Paragraph 5. Retrieved 2008-10-25.
  19. ^ Mehta, Aalok (2005-06-20). "Aspirin". Chemical & Engineering News. 83 (25). Retrieved 2008-10-23.
  20. ^ http://www.ul.ie/~childsp/CinA/Issue59/TOC43_Aspirin.htm
  21. ^ CBE Style Manual Committee; Huth, Edward J. (1994). Scientific Style and Format: The CBE Manual for Authors, Editors, and Publishers. Cambridge University Press. p. 164.{{cite book}}: CS1 maint: multiple names: authors list (link)
  22. ^ http://www.cbc.ca/health/story/2009/05/28/f-aspirin-studies.html
  23. ^ Cheng, Tsung O. (2007). "The History of Aspirin". Texas Heart Institute Journal. 34 (3): 392–393. PMID 17948100. Retrieved 2008-10-23. {{cite journal}}: Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  24. ^ http://www.pharmainfo.net/zarrinfaria/aspirin
  25. ^ http://www.trademarkia.com/company-bayer-aktiengesellschaft-131972-page-1-2
  26. ^ Tfelt-Hansen P (2008). "Triptans vs Other Drugs for Acute Migraine. Are There Differences in Efficacy? A Comment". Headache. 48: 601–605. PMID 18377382.
  27. ^ Lampl C, Voelker M, Diener HC (2007). "Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms". J Neurol. 254: 705–712. PMID 17406776.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  28. ^ a b Diener HC, Bussone G, de Liano H; et al. (2004). "The fixed combination of acetylsalicylic acid, paracetamol and caffeine is more effective than single substances and dual combination for the treatment of headache: a multicentre, randomized, double-blind, single-dose, placebo-controlled parallel group study". Cephalalgia. 25 (10): 776–787. PMID 16162254. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  29. ^ Diener HC, Pfaffenrath V, Pageler L; et al. (2004). "Efficacy and safety of 1,000 mg effervescent aspirin: individual patient data meta-analysis of three trials in migraine headache and migraine accompanying symptoms". Cephalalgia. 24 (11): 947–54. PMID 15482357. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  30. ^ Goldstein J, Silberstein SD, Saper JR; et al. (2006). "Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study". Headache. 46 (3): 444–53. PMID 16618262. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  31. ^ Goldstein J, Silberstein SD, Saper JR; et al. (2005). "Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial". Headache. 45 (8): 973–82. PMID 16109110. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link)
  32. ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 11472387, please use {{cite journal}} with |pmid=11472387 instead.
  33. ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 12534583, please use {{cite journal}} with |pmid=12534583 instead.
  34. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 8706118, please use {{cite journal}} with |pmid=8706118 instead.
  35. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 7955822, please use {{cite journal}} with |pmid=7955822 instead.
  36. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14592563, please use {{cite journal}} with |pmid=14592563 instead.
  37. ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10868553, please use {{cite journal}} with |pmid=10868553 instead.
  38. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9373807, please use {{cite journal}} with |pmid=9373807 instead.
  39. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 6763202, please use {{cite journal}} with |pmid=6763202 instead.
  40. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9692420, please use {{cite journal}} with |pmid=9692420 instead.
  41. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 9268956, please use {{cite journal}} with |pmid=9268956 instead.
  42. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 18458355, please use {{cite journal}} with |pmid=18458355 instead.
  43. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14622688, please use {{cite journal}} with |pmid=14622688 instead.
  44. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 10896014, please use {{cite journal}} with |pmid=10896014 instead.
  45. ^ a b Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 16154478, please use {{cite journal}} with |pmid=16154478 instead.
  46. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 12873261, please use {{cite journal}} with |pmid=12873261 instead.
  47. ^ a b c National Heart Foundation of Australia (RF/RHD guideline development working group) and the Cardiac Society of Australia and New Zealand (June 2006). "Diagnosis and management of acute rheumatic fever and rheumatic heart disease in Australia. An evidence-based review" (PDF). National Heart Foundation of Australia. pp. 33–37. Retrieved 2009-11-01.
  48. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14651540, please use {{cite journal}} with |pmid=14651540 instead.
  49. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 1376585, please use {{cite journal}} with |pmid=1376585 instead.
  50. ^ Attention: This template ({{cite pmid}}) is deprecated. To cite the publication identified by PMID 14517527, please use {{cite journal}} with |pmid=14517527 instead.
  51. ^ Hsieh KS, Weng KP, Lin CC, Huang TC, Lee CL, Huang SM (2004). "Treatment of acute Kawasaki disease: aspirin's role in the febrile stage revisited". Pediatrics. 114 (6): e689–93. doi:10.1542/peds.2004-1037. PMID 15545617. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  52. ^ Krumholz, HM (1995-11-15). "Aspirin in the treatment of acute myocardial infarction in elderly Medicare beneficiaries. Patterns of use and outcomes". Circulation. 92 (10): 2841–7. PMID 7586250. {{cite journal}}: |access-date= requires |url= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  53. ^ ISIS-2 Collaborative group (1988). "Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2". Lancet (2): 349–60. PMID 2899772.{{cite journal}}: CS1 maint: numeric names: authors list (link)
  54. ^ P S Sanmuganathan, P Ghahramani, P R Jackson, E J Wallis, L E Ramsay (2001). "Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials". Heart. 85: 265–271. {{cite journal}}: Text "doi:10.1136/heart.85.3.265/http://heart.bmj.com/cgi/content/abstract/85/3/265" ignored (help)CS1 maint: multiple names: authors list (link)
  55. ^ Chew EY, Williams GA, Burton TC, Barton FB, Remaley NA, Ferris FL (1992). "Aspirin effects on the development of cataracts in patients with diabetes mellitus. Early treatment diabetic retinopathy study report 16". Arch Ophthalmol. 110 (3): 339–42. PMID 1543449.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  56. ^ Bosetti; et al. (2006). "Aspirin and the risk of prostate cancer". Eur J Cancer Prev. 15 (1): 43–5. doi:10.1097/01.cej.0000180665.04335.de. PMID 16374228. {{cite journal}}: Explicit use of et al. in: |author= (help)
  57. ^ Menezes; et al. (2006). "Regular use of aspirin and prostate cancer risk (United States)". Cancer Causes & Control. 17 (3): 251–6. doi:10.1007/s10552-005-0450-z. PMID 16489532. {{cite journal}}: Explicit use of et al. in: |author= (help)
  58. ^ Schernhammer; et al. (2004). "A Prospective Study of Aspirin Use and the Risk of Pancreatic Cancer in Women". J Natl Cancer Inst. 96 (1): 22–28. doi:10.1093/jnci/djh001. PMID 14709735. {{cite journal}}: Explicit use of et al. in: |author= (help)
  59. ^ Larsson SC, Giovannucci E, Bergkvist L, Wolk A (2006). "Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis". Cancer Epidemiol. Biomarkers Prev. 15 (12): 2561–4. doi:10.1158/1055-9965.EPI-06-0574. PMID 17164387. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  60. ^ Thun MJ, Namboodiri MM, Heath CW (1991). "Aspirin use and reduced risk of fatal colon cancer". N Engl J Med. 325 (23): 1593–6. PMID 1669840.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  61. ^ Baron; et al. (2003). "A randomized trial of aspirin to prevent colorectal adenomas". N Engl J Med. 348 (10): 891–9. doi:10.1056/NEJMoa021735. PMID 12621133. {{cite journal}}: Explicit use of et al. in: |author= (help)
  62. ^ Chan; et al. (2004). "A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma". Ann Intern Med. 140 (3): 157–66. PMID 14757613. {{cite journal}}: Explicit use of et al. in: |author= (help)
  63. ^ Chan; et al. (2005). "Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer". JAMA. 294 (8): 914–23. doi:10.1001/jama.294.8.914. PMID 16118381. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |doi_brokendate= ignored (|doi-broken-date= suggested) (help)
  64. ^ Akhmedkhanov; et al. (2002). "Aspirin and lung cancer in women". Br J cancer. 87 (11): 1337–8. doi:10.1038/sj.bjc.6600370. PMID 12085255. {{cite journal}}: Explicit use of et al. in: |author= (help)
  65. ^ Moysich KB, Menezes RJ, Ronsani A; et al. (2002). "Regular aspirin use and lung cancer risk". BMC Cancer. 2: 31. doi:10.1186/1471-2407-2-31. PMID 12453317. {{cite journal}}: Explicit use of et al. in: |author= (help)CS1 maint: multiple names: authors list (link) CS1 maint: unflagged free DOI (link) Free full text
  66. ^ a b Jayaprakash, Vijayvel (2006-07-01). "Regular aspirin use and esophageal cancer risk". Int J Cancer. 119 (1): 202–7. doi:10.1002/ijc.21814. PMID 16450404. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  67. ^ Bosetti; et al. (2003). "Aspirin use and cancers of the upper aerodigestive tract". Br J Cancer. 88 (5): 672–74. doi:10.1038/sj.bjc.6600820. PMID 12618872. {{cite journal}}: Explicit use of et al. in: |author= (help)
  68. ^ Wolff; et al. (1998). "Expression of cyclooxygenase-2 in human lung carcinoma". Cancer Research. 58 (22): 4997–5001. PMID 9823297. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  69. ^ Imaeda, Avlin B.; Watanabe, Azuma; Sohail, Muhammad A.; Mahmood, Shamail; Mohamadnejad, Mehdi; Sutterwala, Fayyaz S.; Flavell, Richard A.; Mehal, Wajahat Z. (2009), "Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the Nalp3 inflammasome", Journal of Clinical Investigation, doi:10.1172/JCI35958
  70. ^ Chan; et al. (209). "Aspirin Use and Survival After Diagnosis of Colorectal Cancer". JAMA. 302 (6): 649–658. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  71. ^ PGxNews.Org (2009). "Aspirin use after colorectal cancer diagnosis associated with improved survival". PGxNews.Org. Retrieved 2009-08-11. {{cite web}}: Unknown parameter |month= ignored (help)
  72. ^ Crosby, Janet Tobiassen (2006). "Veterinary Questions and Answers". About.com. Retrieved 2007-09-05.
  73. ^ Cambridge H, Lees P, Hooke RE, Russell CS (1991). "Antithrombotic actions of aspirin in the horse". Equine Vet J. 23 (2): 123–7. PMID 1904347.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  74. ^ Lappin, p. 160
  75. ^ John Robert Vane (1971). "Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs". Nature - New Biology. 231 (25): 232–5. PMID 5284360.
  76. ^ Vane JR, Botting RM (2003). "The mechanism of action of aspirin" (PDF). Thromb Res. 110 (5–6): 255–8. doi:10.1016/S0049-3848(03)00379-7. PMID 14592543. {{cite journal}}: Unknown parameter |month= ignored (help)
  77. ^ "Aspirin in Heart Attack and Stroke Prevention". American Heart Association. Retrieved 2008-05-08.
  78. ^ Tohgi, H (1992). "Effects of low-to-high doses of aspirin on platelet aggregability and metabolites of thromboxane A2 and prostacyclin". Stroke. Vol 23: 1400–1403. PMID 1412574. {{cite journal}}: |volume= has extra text (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  79. ^ Somasundaram, S.; et al. (2000). "Uncoupling of intestinal mitochondrial oxidative phosphorylation and inhibition of cyclooxygenase are required for the development of NSAID-enteropathy in the rat". Aliment Pharmacol Ther. 14: 639–650. doi:10.1046/j.1365-2036.2000.00723.x. Retrieved 2008-05-28. {{cite journal}}: Explicit use of et al. in: |last= (help)
  80. ^ Mark J. Paul-Clark, Thong van Cao, Niloufar Moradi-Bidhendi, Dianne Cooper, and Derek W. Gilroy 15-epi-lipoxin A4–mediated Induction of Nitric Oxide Explains How Aspirin Inhibits Acute Inflammation J. Exp. Med. 200: 69-78; published online before print as 10.1084/jem.20040566
  81. ^ McCarty, MF (2006). "Preadministration of high-dose salicylates, suppressors of NF-kappaB activation, may increase the chemosensitivity of many cancers: an example of proapoptotic signal modulation therapy". Integr Cancer Ther. Vol 5 (3): 252–268. doi:10.1177/1534735406291499. PMID 16880431. {{cite journal}}: |volume= has extra text (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  82. ^ a b Nye EJ, Hockings GI, Grice JE, Torpy DJ, Walters MM, Crosbie GV, Wagenaar M, Cooper M, Jackson RV. (1997). Aspirin inhibits vasopressin-induced hypothalamic-pituitary-adrenal activity in normal humans. J Clin Endocrinol Metab. 82(3):812-7. PMID 9062488
  83. ^ Hockings GI, Grice JE, Crosbie GV, Walters MM, Jackson AJ, Jackson RV. (1993). Aspirin increases the human hypothalamic-pituitary-adrenal axis response to naloxone stimulation. J Clin Endocrinol Metab. 77(2):404-8. PMID 8393884
  84. ^ Reynolds EF (ed) (1982). Aspirin and similar analgesic and anti-inflammatory agents. Martindale, The Extra Pharmacopoeia 28 Ed, 234-82.
  85. ^ Palleros, Daniel R. (2000). Experimental Organic Chemistry. New York: John Wiley & Sons. p. 494. ISBN 0-471-28250-2.
  86. ^ Barrans, Richard. "Aspirin Aging". Newton BBS. Retrieved 2008-05-08.
  87. ^ Carstensen, J.T. (1985). "Decomposition of aspirin in the solid state in the presence of limited amounts of moisture". Journal of Pharmaceutical Sciences. 77 (4): 318–21. doi:10.1002/jps.2600770407. PMID 4032246. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help); Unknown parameter |month= ignored (help)
  88. ^ "Acetylsalicylic acid". Jinno Laboratory, School of Materials Science, Toyohashi University of Technology. March 1, 1996. Retrieved 2007-09-07. {{cite web}}: Check date values in: |date= (help)
  89. ^ Peddy Vishweshwar, Jennifer A. McMahon, Mark Oliveira, Matthew L. Peterson, and Michael J. Zaworotko (2005). "The Predictably Elusive Form II of Aspirin". J. Am. Chem. Soc. 127 (48): 16802–16803. doi:10.1021/ja056455b.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  90. ^ Andrew D. Bond, Roland Boese, Gautam R. Desiraju (2007). "On the Polymorphism of Aspirin: Crystalline Aspirin as Intergrowths of Two "Polymorphic" Domains". Angewandte Chemie International Edition. 46 (4): 618–622. doi:10.1002/anie.200603373.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  91. ^ Ferguson, RK (1970-08-17). "Death following self-poisoning with aspirin". Journal of the American Medical Association. PMID 5468267. {{cite journal}}: Unknown parameter |coauthors= ignored (|author= suggested) (help)
  92. ^ Kaufman, FL (1970-04). "Darvon poisoning with delayed salicylism: a case report". Pediatrics. 49 (4): 610–1. PMID 5013423. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  93. ^ a b c Levy, G (1972-09-31). "Salicylate accumulation kinetics in man". New England Journal of Medicine. 287 (9): 430–2. PMID 5044917. {{cite journal}}: Check date values in: |date= (help); Unknown parameter |coauthors= ignored (|author= suggested) (help)
  94. ^ Hartwig, Otto H (1983-11-14). "Pharmacokinetic considerations of common analgesics and antipyretics". American Journal of Medicine. 75 (5A): 30–7. doi:10.1016/0002-9343(83)90230-9. PMC 1725844. PMID 6606362. {{cite journal}}: Cite has empty unknown parameter: |coauthors= (help)
  95. ^ Done, AK (1960-11). "Salicylate intoxication. Significance of measurements of salicylate in blood in cases of acute ingestion". Pediatrics: 800–7. PMID 13723722. {{cite journal}}: Check date values in: |date= (help); Cite has empty unknown parameter: |coauthors= (help)
  96. ^ Chyka PA, Erdman AR, Christianson G, Wax PM, Booze LL, Manoguerra AS, Caravati EM, Nelson LS, Olson KR, Cobaugh DJ, Scharman EJ, Woolf AD, Troutman WG; Americal Association of Poison Control Centers; Healthcare Systems Bureau, Health Resources and Services Administration, Department of Health and Human Services. (2007). "Salicylate poisoning: an evidence-based consensus guideline for out-of-hospital management". Clin Toxicol (Phila). 45 (2): 95–131. doi:10.1080/15563650600907140. PMID 17364628.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  97. ^ Prescott LF, Balali-Mood M, Critchley JA, Johnstone AF, Proudfoot AT (1982). "Diuresis or urinary alkalinisation for salicylate poisoning?". Br Med J (Clin Res Ed). 285 (6352): 1383–6. doi:10.1136/bmj.285.6352.1383. PMC 1500395. PMID 6291695. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  98. ^ Dargan PI, Wallace CI, Jones AL. (2002). "An evidenced based flowchart to guide the management of acute salicylate (aspirin) overdose". Emerg Med J. 19 (3): 206–9. doi:10.1136/emj.19.3.206. PMC 1725844. PMID 11971828.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  99. ^ a b c d e "Aspirin information from Drugs.com". Drugs.com. Retrieved 2008-05-08.
  100. ^ a b c "Oral Aspirin information". First DataBank. Retrieved 2008-05-08.
  101. ^ Raithel M, Baenkler HW, Naegel A; et al. (2005). "Significance of salicylate intolerance in diseases of the lower gastrointestinal tract" (PDF). J. Physiol. Pharmacol. 56 Suppl 5: 89–102. PMID 16247191. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  102. ^ Senna GE, Andri G, Dama AR, Mezzelani P, Andri L (1995). "Tolerability of imidazole salycilate in aspirin-sensitive patients". Allergy Proc. 16 (5): 251–4. doi:10.2500/108854195778702675. PMID 8566739.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  103. ^ a b PDR Guide to Over the Counter (OTC) Drugs, retrieved 2008-04-28.
  104. ^ G6PD (Glucose-6-Phosphate Dehydrogenase) Deficiency, University of Virginia, retrieved 2008-05-07
  105. ^ G6PD (Glucose-6-Phosphate Dehydrogenase) Deficiency, University of Texas Medical Branch, retrieved 2008-05-07
  106. ^ Dengue and Dengue Hemorrhagic Fever: Information for Health Care Practitioners, retrieved 2008-04-28
  107. ^ Dorsch MP, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS (2007). "Aspirin Resistance in Patients with Stable Coronary Artery Disease with and without a History of Myocardial Infarction". Ann Pharmacother. 41 (May): 737. doi:10.1345/aph.1H621. PMID 17456544. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  108. ^ Krasopoulos G, Brister SJ, Beattie WS, Buchanan MR (2008). "Aspirin "resistance" and risk of cardiovascular morbidity: systematic review and meta-analysis". BMJ. 336 (7637): 195–8. doi:10.1136/bmj.39430.529549.BE. PMC 2213873. PMID 18202034. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  109. ^ Pignatelli P, Di Santo S, Barillà F, Gaudio C, Violi F (2008). "Multiple anti-atherosclerotic treatments impair aspirin compliance: effects on aspirin resistance". J. Thromb. Haemost. 6 (10): 1832–4. doi:10.1111/j.1538-7836.2008.03122.x. PMID 18680540. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  110. ^ a b c Sørensen HT, Mellemkjaer L, Blot WJ; et al. (2000). "Risk of upper gastrointestinal bleeding associated with use of low-dose aspirin". Am. J. Gastroenterol. 95 (9): 2218–24. doi:10.1111/j.1572-0241.2000.02248.x. PMID 11007221. {{cite journal}}: Explicit use of et al. in: |author= (help); Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  111. ^ Delaney JA, Opatrny L, Brophy JM & Suissa S (2007). "Drug drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding". CMAJ. 177 (4): 347–51. doi:10.1503/cmaj.070186. PMC 1942107. PMID 17698822. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  112. ^ Guitton MJ, Caston J, Ruel J, Johnson RM, Pujol R, Puel JL (2003). "Salicylate induces tinnitus through activation of cochlear NMDA receptors". J. Neurosci. 23 (9): 3944–52. PMID 12736364. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  113. ^ a b Belay ED, Bresee JS, Holman RC, Khan AS, Shahriari A, Schonberger LB (1999). "Reye's syndrome in the United States from 1981 through 1997". N. Engl. J. Med. 340 (18): 1377–82. doi:10.1056/NEJM199905063401801. PMID 10228187. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  114. ^ Scher, K.S. (1996). "Unplanned reoperation for bleeding". Am Surg. 62 (1): 52–55. PMID 8540646. {{cite journal}}: Unknown parameter |month= ignored (help)
  115. ^ Berges-Gimeno MP & Stevenson DD (2004). "Nonsteroidal anti-inflammatory drug-induced reactions and desensitization". J Asthma. 41 (4): 375–84. doi:10.1081/JAS-120037650. PMID 15281324. {{cite journal}}: Unknown parameter |month= ignored (help)
  116. ^ Vernooij MW, Haag MD, van der Lugt A, Hofman A, Krestin GP, Stricker BH, Breteler MM. (2009). Use of antithrombotic drugs and the presence of cerebral microbleeds: the Rotterdam Scan Study. Arch Neurol. 66(6):714-20. PMID 19364926 [
  117. ^ Gorelick PB. (2009). Cerebral microbleeds: evidence of heightened risk associated with aspirin use. Arch Neurol. 66(6):691-3. PMID 19506128
  118. ^ {{cite journal |author=Neely J, Rosen C |month=June |year=2000 |title=Vocal fold haemorrhage associated with coumadin therapy in an opera singer |journal=Journal of Voice |volume=14 |issue=2 |pages=272–277 }
  119. ^ Katzung (1998), p. 584.
  120. ^ Loh HS, Watters K & Wilson CW (1973). "The Effects of Aspirin on the Metabolic Availability of Ascorbic Acid in Human Beings". J Clin Pharmacol. 13 (11): 480–6. PMID 4490672. {{cite journal}}: Unknown parameter |day= ignored (help); Unknown parameter |month= ignored (help)
  121. ^ Basu TK (1982). "Vitamin C-aspirin interactions". Int J Vitam Nutr Res Suppl. 23: 83–90. PMID 6811490. {{cite journal}}: Cite has empty unknown parameter: |month= (help)
  122. ^ Ioannides C, Stone AN, Breacker PJ & Basu TK (1982). "Impairment of absorption of ascorbic acid following ingestion of aspirin in guinea pigs". Biochem Pharmacol. 31 (24): 4035–8. doi:10.1016/0006-2952(82)90652-9. PMID 6818974. {{cite journal}}: Unknown parameter |month= ignored (help)CS1 maint: multiple names: authors list (link)
  123. ^ a b British National Formulary (45 ed.). British Medical Journal and Royal Pharmaceutical Society of Great Britain. 2003. {{cite book}}: Unknown parameter |month= ignored (help)
  124. ^ Aspirin monograph: dosages, etc
  125. ^ [1]
  126. ^ British National Formulary for Children. British Medical Journal and Royal Pharmaceutical Society of Great Britain. 2006.
  127. ^ Gaudreault P, Temple AR, Lovejoy FH Jr. (1982). "The relative severity of acute versus chronic salicylate poisoning in children: a clinical comparison". Pediatrics. 70 (4): 566–9. PMID 7122154.{{cite journal}}: CS1 maint: multiple names: authors list (link)
  128. ^ Marx, John (2006). Rosen's emergency medicine: concepts and clinical practice. Mosby/Elsevier. p. 2242. ISBN 9780323028455. {{cite book}}: Cite has empty unknown parameter: |coauthors= (help)
  129. ^ Sigma Aldrich. "Aspirin". Retrieved 13 July. {{cite web}}: Check date values in: |accessdate= (help); Cite has empty unknown parameter: |coauthors= (help); Unknown parameter |BRAND_KEY&F= ignored (help); Unknown parameter |SIGMA&N5= ignored (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)
  130. ^ British Pharmacopoeia. "Index BP 2009" (PDF). Retrieved 13 July. {{cite web}}: Check date values in: |accessdate= (help); Cite has empty unknown parameter: |coauthors= (help); Unknown parameter |accessyear= ignored (|access-date= suggested) (help)

References

  • Lappin, Michael R. (2001). Feline Internal Medicine Secrets. Elsevier Health Sciences. ISBN 1560534613.
Wikimedia Commons has media related to Aspirin.

Template:Link FA Template:Link FA

Retrieved from "https://en.wikipedia.org/w/index.php?title=Aspirin&oldid=324070645"